79 results about "Barr virus" patented technology

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The invention discloses an NbE7 single-domain antibody, an NbE7-TAT fusion single-domain antibody and application of the NbE7 single-domain antibody and the NbE7-TAT fusion single-domain antibody, the NbE7 single-domain antibody is used for being specifically combined with an EB virus nuclear antigen, the NbE7 single-domain antibody is composed of a framework region FR and a complementary determining region CDR, and the complementary determining region CDR comprises a CDR1 shown in SEQ ID NO.1, a CDR2 shown in SEQ ID NO.2 and a CDR3 shown in SEQ ID NO.3. The NbE7 single-domain antibody is used for being specifically combined with an EB virus nuclear antigen. The NbE7-TAT fusion single-domain antibody is a fusion protein of an NbE7 single-domain antibody and a TAT peptide fragment of an HIV-1 virus. The NbE7 single-domain antibody and the NbE7-TAT fusion single-domain antibody provided by the invention provide a new thought for the development of drugs for treating EBV latent infection and EB virus related tumors.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The present invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes Epstein-Barr virus gp42 protein and its application. The monoclonal antibody or its antigen-binding fragment has good binding activity with gp42 protein, has high affinity for gp42 protein, can specifically recognize natural gp42 protein expressed on the cell surface, can significantly inhibit EBV infection of B cells, and effectively inhibits cell membrane fusion. It can be used to detect the presence or level of gp42 protein in a sample, detect Epstein-Barr virus, diagnose diseases caused by Epstein-Barr virus infection, prevent Epstein-Barr virus infection, and / or treat and / or prevent diseases caused by Epstein-Barr virus infection.

This disclosure concerns methods of analysing and sequencing viral genomic DNA, in particular Epstein-Barr virus (EBV) genomic DNA, using viral-specific nucleic acid capture probes and long read sequencing.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The present disclosure provides antibodies, and antigen binding fragments thereof, which bind an extracellular domain region of an Epstein-Barr virus (EBV) membrane protein, and related nucleic acids, vectors, pharmaceutical compositions, cells, and methods of use thereof. The antibodies, and antigen binding fragments thereof, as described herein can find utility as therapeutic and diagnostic agents for EBV infections and EBV-mediated diseases or as research agents.

The present application belongs to the field of medicine, and particularly relates to an EBNA1 inhibitor. The small molecule inhibitor recorded in the present application is proved by surface plasmon resonance (SPR) analysis to interact with EBNA1 in vitro and have high affinity, significantly inhibit the function of EBNA1 at the cell level, significantly down-regulate the copy number of the Epstein-Barr virus (EBV) genome of PBMC of a nasopharyngeal carcinoma patient in vitro, have good biological safety in mice, provide a new treatment strategy for patients with EB virus positive tumors, and have far-reaching clinical significance and popularization.

The invention provides a risk prediction system and application of EB virus related hemophagocytic syndrome patients, five indexes UREA, DB, hscTnI, Ferr and PT are researched and developed to construct a scoring system, and if the score is greater than or equal to 3, the patient is prompted that the 28-day prognosis adverse risk is obviously increased (OR = 1.915). The model can provide a dynamic risk assessment tool for clinic and guide individualized treatment decisions.

The application discloses a spinal muscular atrophy quality control product and a preparation method and application thereof. The application aims at the deficiency that the existing method of using Epstein-Barr virus to immortalize lymphocytes cannot efficiently transform spinal muscular atrophy lymphocytes into immortalized cells, and provides a transformation culture medium and a method for constructing immortalized spinal muscular atrophy lymphocytes by using the culture medium. By using the method, the immortalized spinal muscular atrophy lymphocyte strain can be constructed within 30 days, and the corresponding immortalized cell line can be obtained by subculturing the immortalized spinal muscular atrophy lymphocyte strain. When the immortalized spinal muscular atrophy lymphocytes are constructed by using the method, the required time is short, the success rate is high, the genetic background of the obtained immortalized cells is stable, the interoperability with clinical samples is high, the compatibility is good, the immortalized cells can be stably preserved, and the immortalized cells can be used as positive quality control products in gene detection of spinal muscular atrophy, so that the accuracy of detection can be ensured.

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

The present invention relates to the field of immunotherapy, in particular to diseases associated with Epstein-Barr virus (EBV, also known as human gamma herpesvirus 4), such as cancer or post-transplant lymphoproliferative disease, in particular to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The present invention provides a combination of nucleic acids encoding at least two TCR constructs or corresponding proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of a respective MHC I, and wherein the epitopes are derived from different antigens expressed by the same infectious agent or cancer, such as EBV antigens. The present invention further provides specific nucleic acids encoding a TCR alpha chain construct (TRA) and / or a TCR beta chain construct (TRB) of a TCR construct specific for an epitope complexed with human MHC I, wherein the epitope is an epitope of an Epstein-Barr virus protein, the TCR construct being specific for an epitope from LMP2A, LMP1 or EBNA3C. Proteins encoded by said nucleic acids, corresponding host cells, as well as pharmaceutical compositions and kits are also an object of the present invention.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes encoding Epstein-Barr Virus (EBV) proteins, e.g., gp350, gH, gL, and gp42, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding EBV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to EBV in subjects.

Epstein-Barr virus (EBV) antigen composites and a dendritic cell (DC)-based vaccine, and a use thereof in preparation of a drug for controlling an EBV-associated infectious disease are provided. Patient-derived DCs are stimulated in vitro, loaded with lysates of various types of EBV-infected cells with strong immunogenicity for EBV-associated infectious diseases, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists, so as to obtain a complete DC-based vaccine with corresponding antigens. The DC-based vaccine can be injected back into the patient to activate the immune system to produce cytotoxic T cells, thereby killing EBV-infected cells, exerting an immunological effect, and improving a life quality of the patient. In addition, the DC-based vaccine can be prepared in about one week with a low cost, is safe, and shows no obvious side effects.

The present application describes T cell receptors specifically binding tumor antigen derived peptides, especially derived from Mitogen-Activated Protein Kinase 8 Interacting Protein 2 (MAPK8IP2), Epstein-Barr Virus (EBV) proteins or Human Endogenous Retrovirus (HERV), as well as engineered T cells expressing these receptors, nucleic acids encoding these T cell receptors and methods of using T cells expressing these engineered T cells in adoptive cell transfer to treat diseases in a subject.

This invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes the Epstein-Barr virus (EBV) gp350 protein and its applications. This invention provides a monoclonal antibody against the EBV gp350 protein or its antigen-binding fragment, comprising 1A12 and 2E4, wherein 1A12 has a high affinity for the gp350 protein (KD(M) = 3.415E). ‑10 ), 2E4 has a high affinity for gp350 protein (KD(M) = 4.851E). ‑9 These two monoclonal antibodies or their antigen-binding fragments can significantly inhibit EBV infection of epithelial cells and B cells. They can be used to detect the presence or level of gp350 protein in samples, detect EBV, diagnose diseases caused by EBV infection, prevent EBV infection and / or treat and / or prevent diseases caused by EBV infection.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

Provided herein are compositions comprising Epstein-Barr Virus envelope proteins (e.g., glycoprotein 350 (gp350)) and saponin adjuvant and methods of using the aforementioned compositions for inducing an immune response against Epstein-Barr Virus.

Methods and oligonucleotide reagents for genotyping Epstein-Barr virus are disclosed. In particular, genetic profiling is used to detect BALF2 variants in the genome of Epstein-Barr virus in an infected individual to predict the risk of an individual developing nasopharyngeal carcinoma. Primers and allele-specific probes are provided for performing nucleic acid-based diagnostic assays to determine which alleles are present at single nucleotide polymorphisms (SNPs) in the BALF2 gene of Epstein-Barr virus in biological samples from potentially infected subjects. These primers and allele-specific probes can be used for amplifying target sequences to allow rapid detection of a single mutation or multiple mutations in the BALF2 gene simultaneously in a single assay. In addition, methods are provided for identifying individuals at high risk of developing nasopharyngeal carcinoma who are in need of further screening and treatment.

The invention provides a probe and a kit for detecting EB (Epstein-Barr) virus and application of the probe and the kit. The probes comprise a probe specifically combined with an EBER1 gene and a probe specifically combined with an EBER2 gene; the nucleotide sequence of the probe is shown as any one of SEQ ID NO: 1 to SEQ ID NO: 18. On the basis of the probe, multi-Dig labeling and locked nucleic acid modification are carried out, so that the developing intensity, the probe hybridization efficiency and the stability are improved. On the basis, the probes are combined for use, after combined use, the developing background is further reduced, the specificity is enhanced, and the detection effect is further improved.

The present application relates to the field of biological detection technology, and more particularly to a primer set, a probe, a kit, and applications thereof, wherein the primer set includes an amplification primer pair. The sequence of the amplification primer pair includes an upstream primer and a downstream primer. The primer set and the probe are used to detect Epstein-Barr virus.

This invention relates to providing automated systems and computer-implemented methods for detecting diseases such as nasopharyngeal carcinoma (NPC) based on the analysis of immunofluorescence assay (IFA) images using fuzzy inference (FI) systems or deep learning fuzzy inference (DeLFI) hybrid models. For NPC detection, the systems and methods of this invention will distinguish between Epstein-Barr virus (EBV) early antigen (EA) positive and negative cells and identify cellular patterns indicative of NPC. DeLFI hybrid models require less human evaluation and therefore have the potential to improve the scalability and accuracy of NPC detection.

The invention belongs to the technical field of biological medicine, and relates to a method for inhibiting EB (Epstein-Barr) virus based on a KLRG1 target spot and application. Specifically, the invention provides an application of a KLRG1 inhibitor in prevention and / or treatment of chronic active EB virus infection CAEBV. The invention also provides an application of the KLRG1 detection reagent in auxiliary detection of the CAEBV, and provides a method for screening a potential therapeutic agent for treating the CAEBV.